Corcept Therapeutics Inc

NASDAQ:CORTUnited States

Oct 30, 2024

Show headlines and story abstract

• -- Earnings Flash (CORT) CORCEPT THERAPEUTICS INCORPORATED Posts Q3 EPS $0.41, from 4:37PM ET on Wednesday Oct 30, 2024 by MT Newswires

  4:37PM ET on Wednesday Oct 30, 2024 by MT Newswires
  Companies Mentioned: CORT
  04:37 PM EDT, 10/30/2024 (MT Newswires) -- ...

• Corcept Therapeutics Announces Third Quarter Financial Results, Positive Results From Phase 3 GRADIENT Trial in Patients With Cushing's Syndrome and Provides Corporate Update, from 4:05PM ET on Wednesday Oct 30, 2024 by Dow Jones

  4:05PM ET on Wednesday Oct 30, 2024 by Dow Jones
  Companies Mentioned: CORT
  
  "Relacorilant has the potential to become the standard of care for patients with platinum-resistant ovarian cancer. If ROSELLA replicates the positive results of our large, controlled, Phase 2 study, it will constitute a major medical advance and serve as the basis for relacorilant's next NDA. We expect progression-free survival data, ROSELLA's primary endpoint, by the end of this year," said Dr. Guyer.
  

• *DJ Corcept Therapeutics 3Q EPS 41c >CORT, from 4:05PM ET on Wednesday Oct 30, 2024 by Dow Jones

  4:05PM ET on Wednesday Oct 30, 2024 by Dow Jones
  Companies Mentioned: CORT
  
  "Relacorilant has the potential to become the standard of care for patients with platinum-resistant ovarian cancer. If ROSELLA replicates the positive results of our large, controlled, Phase 2 study, it will constitute a major medical advance and serve as the basis for relacorilant's next NDA. We expect progression-free survival data, ROSELLA's primary endpoint, by the end of this year," said Dr. Guyer.